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Sllnlnlagy 
CD38 is a transmembrane glycoprotein expressed in many cell types, including lymphoid pro- 
genitors and activated lymphocytes. High levels of CD38 expression on immature lymphoid cells 
suggest its role in the regulation of cell growth and differentiation, but there is no evidence 
demonstrating a functional activity of CD38 on these cells. We used stroma-supported cultures 
of B cell progenitors and anti-CD38 monodonal antibodies (T16 and IB4) to study CD38 func- 
tion. In cultures of normal bone marrow CD19 + cells (n  =  5), addition of anti-CD38 markedly 
reduced the number of cells recovered after 7 d.  Cell loss was greatest among CD19 § slg-  B 
cell progenitors (mean cell recovery +_ SD  =  7.2  _  11.7%  of recovery in control cultures) and 
extended to CD19~CD34 + B cells (the most immature subset; 7.6  •  2.2%). In contrast, CD38 
ligation did not substantially affect cell numbers in cultures of normal peripheral blood or ton- 
siUar B cells. In stroma-supported cultures of 22 B-lineage acute lymphoblastic leukemia cases, 
anti-CD38  suppressed recovery of CD19 +  slg-  leukemic calls. CD38 ligation also suppressed 
the growth of immature lymphoid cell lines cultured on stroma and, in some cases, in the pres- 
ence of stroma-derived cytokines (interleukin [IL] 7, II-3, and/or stem cell factor), but did not 
inhibit growth in stroma- or cytokine- free cultures. DNA content and DNA  fragmentation 
studies showed that CD38 ligation of stroma-supported cells resulted in both inhibition of DNA 
synthesis and induction of apoptosis.  It is known that CD38  catalyzes nicotinamide adenine 
dinudeotide (NAD+) hydrolysis into cyclic ADP-ribose (cADPR) and ADPR.  However, no 
changes in NAD+  hydrolysis or cADPR and ADPR production after CD38 ligation were found 
by high-performance liquid chromatography; addition of NAD+, ADPIL, or cADPK to cul- 
tures of lymphoid progenitors did not offset the inhibitory effects of anti-CD38.  Thus, anti- 
CD38 does not suppress  B lymphopoiesis by altering the enzymatic function of the molecule. 
In conclusion, these data show that CD38 ligation inhibits the growth of immature B lymphoid 
cells in the bone marrow microenvironment, and suggest that CD38 interaction with a putative 
ligand represents a novel regulatory mechanism of B lymphopoiesis. 
C 
D38,  a 45-kD transmembrane glycoprotein, is highly 
expressed on the surface of lymphoid, myeloid, and 
erythroid progenitor cells,  activated T  and B lymphocytes, 
NK cells, and plasma ceils (1-6). In most cases of acute lym- 
phoblastic leukemia (ALL) 1, leukemic cells- the malignant 
counterparts of immature lymphoid cells-  are also CD38 § 
(1, 3,  4). 
1Abbreviations used in this paper: ALL, acute lymphoblastic leukemia; 
cADPR, cyclic  ADP-ribose; NAD +, nicotinamide  adenine  dinudeotide; 
PBSA, PBS containing 0.2% BSA and 0.2% sodium azide; SCF, stem 
cell factor; slg, surface Ig. 
Little is known about the biologic function and physio- 
logic role of CD38.  Ligation of CD38 with specific anti- 
bodies has a stimulatory effect on cultured lymphocytes (7), 
and it enhances DNA synthesis in the presence of other stimuli 
such as CD3, IL-4, and I1-2 plus accessory cells (7-9).  En- 
gagement of CD38 also rescues germinal center cells from 
apoptosis (10) and impairs lymphocyte adhesion to endothelial 
cells (11). Comodulation experiments have shown that CD38 
is physically associated  with CD3 on T  cells, with surface 
Ig, CD19,  and CD21  on B cells,  and with CD16 on NK 
cells (12). Recently, CD38 has been found to be structurally 
homologous to Aplysia  californica ADP-ribosyl cyclase (13), 
an enzyme that catalyzes the conversion of nicotinamide ade- 
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a calcium-mobilizing agent (14). Indeed, CD38 has such en- 
zymatic activity (9, 15-19), suggesting that it may exert its 
effects on lymphocyte function through ADPR cyclase activity, 
although  the precise mechanisms  involved are unclear  (9). 
The strong expression of CD38  on highly proliferating 
progenitor cells in the bone marrow implies a possible role 
of this molecule in the regulation of growth and differentia- 
tion of lymphoid precursors; however, there is no evidence 
to date of CD38's functional activity on these cells. Human 
immature B cells rapidly die in vitro unless they are supported 
by bone marrow-derived stromal cells (20).  The establish- 
ment of tissue culture methods  that prevent apoptotic cell 
death and sustain the growth of normal and leukemic imma- 
ture B  cells has opened the opportunity  to investigate the 
molecules that influence human B  lymphopoiesis (20-23). 
In this study, we used anti-CD38 mAbs and stroma-supported 
cultures of B cell progenitors to investigate the function of 
CD38 during normal and leukemic B cell differentiation and 
found that ligation of CD38 suppresses survival and growth 
of normal and leukemic immature  B  cells. 
Materials and Methods 
Cells.  Bone marrow samples were taken,  with informed con- 
sent and Institutional Review Board approval, from 5 healthy bone 
marrow transplant donors, aged 2-30 yr (median, 10 yr), and from 
22 patients with newly diagnosed B-lineage  ALL, aged  1-18 yr 
(median,  5  yr).  Diagnosis  was  unequivocal  by  morphologic, 
cytochemical, and immunophenotypic criteria. In each case of ALL, 
>80% of the blasts were positive for CD19, CD22, terminal deoxy- 
nucleotidyl transferase,  and MHC-class II antigens,  and negative 
for surface Ig. Peripheral blood samples were obtained from healthy 
adult donors. Tonsils were obtained from routine tonsillectomies; 
cell suspensions were prepared by use of forceps and surgical blades. 
Mononuclear cells were collected after centrifugation on a density 
gradient (Lymphoprep; Nycomed, Oslo, Norway) and washed three 
times in PBS and once in AIM-V  medium (Gibco Laboratories, 
Grand Island,  NY). Normal CD19 + bone marrow and peripheral 
blood cells were purified by use of CD19-immunomagnetic beads 
(Dynal, Oslo, Norway). Cells  were detached from the beads by 
use of a goat antiserum to mouse Ig Fab (DETACHaBEAD; Dynal). 
At the end of the procedure,  90-98% of cells were CD19 +. T cells 
were removed from suspensions  of tonsillar lymphocytes by use 
of a mixture of magnetic beads conjugated to CD4 and CD8 anti- 
bodies (Dynal). Cell-sorting procedures were performed according 
to  the  manufacturer's  instructions.  Immature  B  lineage  ALL 
(RS4;11, OP-1, 380, REH, 697, NALM6), Burkitt's lymphoma 
(RAJI) and T-lineage ALL (MOLT4, CEM-C7) cell lines were ob- 
tained from our cell bank; the EBV- transformed B lymphoblastoid 
cell line J.R. was obtained by EBV infection of peripheral blood 
B lymphocytes from a healthy individual.  All cell lines were main- 
tained in RPMI-1640 (Whittaker Bioproducts Inc., WalkersviUe, 
MD) with 10% FCS (Whittaker Bioproducts Inc.),  L-glutamine, 
and antibiotics. 
To obtain bone marrow stromal cells, we collected mononuclear 
cells from normal marrow donors. The cells were separated as de- 
scribed above and washed three times in RPMI-1640.  Stromal layers 
were prepared in flat-bottomed 96- or 24-well plates (Costar Corp., 
Cambridge,  MA)  and  fed  with  RPMI-1640,  10%  FCS,  and 
10 -6 M bydrocortisone (20,  23-25). 
Cell Culture Studies.  Before each experiment, we removed the 
media from cultures of stromal cells and washed the adherent cells 
seven times with RPMI-1640 to fully remove hydrocortisone (20, 
23-25). Normal and leukemic cells were plated in culture within 
5 h of collection. The cells' viability consistently exceeded 90% 
by trypan blue dye exclusion.  Leukemic and normal cells were 
resuspended  in  serum-flee AIM-V  medium,  and cell lines  were 
resuspended  in RPMI-1640 plus 10% FCS. 200 #1 of the cell sus- 
pension (0.1-1.5 cells  x  106/ml) were then placed in the wells of 
a 96-well flat-bottomed tissue culture plate or seeded onto marrow 
stromal cells in an identical plate. In some experiments, cells were 
cultured separated from stromal layers by use of a 0.4-#m micro- 
porous membrane (Transwell; Costar) (23). All cell cultures were 
incubated at 37~  in 5% CO2 with 90% humidity. At the ter- 
mination of cultures, cells were harvested by vigorous pipetting. 
Microscopic examination of the plates ensured that all cells in the 
wells (i.e., adherent and nonadherent) were recovered.  Cells cul- 
tured on stroma were suspended in PBS and passed through a 19- 
gauge needle to disrupt clumps.  At least two replicate  test were 
performed in each experiment. 
We selected two anti-CD38 mAbs for these studies: T16 oflgG1 
class was purchased from AMAC (Westbrook, ME); IB4 of IgG2a 
class was produced in our laboratories.  Both antibodies have been 
shown to have characteristic CD38 reactivity by both immuno- 
fluorescence and immunoprecipitation (12, 26); T16 was also shown 
to react with COS cells transfected with human CD38 cDNA (27). 
Cross-blocking experiments showed that both antibodies reacted 
with the same epitope (data  not shown). In some experiments, 
F(ab')2 fragments of IB4, produced by standard methods (28), were 
used.  CD38 antibodies and isotype-matched unreactive controls 
were dialyzed in PBS, sterile filtered, and added to the cultures at 
2  /zg/ml,  a  saturating  concentration for the CD38  antibodies. 
Recombinant cytokines IL-3, IL-7, and stem cell factor (SCF) were 
purchased from R&D Systems,  Inc.  (Minneapolis,  MN). 
Flow Cytometric Analysis of Cell Numbers, Cell Cycle, and DNA 
Fragmentation.  Viable cells in culture were enumerated by flow 
cytometry as previously described (20, 23-25). Briefly, harvested 
cells were washed three times in PBS containing 0.2% BSA and 
0.2% sodium azide (PBSA). To assess cell survival, we resuspended 
test and control cells in equal amounts of PBSA. Aliquots of the 
suspensions were placed in Falcon tubes (Becton Dickinson, & Co., 
Lincoln Park,  NJ) and either washed in PBSA and fixed in 0.5% 
paraformaldehyde or incubated with the following antibodies: CD19 
(Leu 12) conjugated to FITC, PE,  or peridin chlorophyl protein 
(PerCP; Becton Dickinson & Co., San Jose, CA); CD34 (HPCA- 
2) conjugated to PE (Becton Dickinson & Co.); CD7 (Leu9) con- 
jugated to FITC (Becton Dickinson & Co.); a mixture of goat 
anti-human  Ig g  +  X light chain antisera  conjugated to FITC 
(Southern Biotechnology  Associates, Birmingham, AL); and/or goat 
anti-human IgD conjugated to FITC (Southern Biotechnology As- 
sociates,  Birmingham,  AL); and/or goat anti-human  IgD con- 
jugated to FITC (Southern Biotechnology Associates).  Isotype- 
matched nonreactive antibodies were used as a control. After two 
washes in PBSA, the cells were resuspended in 0.5% paraformalde- 
hyde and analyzed with a FACScan  |  flow cytometer with Lysis 
II software (Becton Dickinson & Co.). We designed "gates" in the 
light-scattering dot-plots including the vast majority of viable lym- 
phoid cells. Before and after culture, we counted cells with these 
light-scattering properties that passed through the gate within a 
period of time (e.g., 30 s). The results  were corrected according 
to the distribution of ceUs expressing different immunophenotypes. 
Expression of CD38 on various cell types was studied with anti- 
CD38 PE (Becton Dickinson & Co.), which reacts with the same 
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ysis was performed by labeling cells with propidium iodide and 
determining their DNA content by flow cytometry  (FACScan  |  with 
CellFit software; Becton Dickinson & Co.) as described elsewhere 
(29). DNA fragmentation was evaluated  by flow cytometry after 
cell permeabilization and staining with digoxigenin-dUTP, as de- 
scribed by Gold et al. (30). 
Measurement of NAD+  Hydrolase and  ADPR  Cyclase Ac- 
tivity.  Nicotinamide, ~-NAD,  and ADPR were obtained from 
Sigma Chemical Co. (St. Louis, MO). cADPR was obtained from 
Amersham International (Amersham,  UK). Immature B cells (OP-1 
cell line; 31) were washed three times in normal saline solution 
and resuspended at a concentration of 5  x  106 cells/ml. 250/~1 
of the cell suspension was incubated for 30 min at 20"C with anti- 
CD38 (IB4) or a nonreactive  antibody, after which 80 #M NAD+ 
was added. Extracellular concentrations of NAD +, nicotinamide, 
ADPK, and cADPK were determined at different timepoints in 
supernatants obtained after cell centrifugation by HPLC with UV 
detection at 254 nm as described by Lee et al. (32), with slight 
modifications. We used a Partisil 5 SAX (0.46  x  10 cm) column 
(Whatman Inc., Hillsboro, OIL) and a linear gradient of  0.005-0.1 
M ammonium phosphate monobasic in 30 rain at a flow rate of 
1 ml/min. The column was reequilibrated with 0.005 M ammo- 
nium phosphate for an additional 15 min before the next injection. 
Standards for nicotinamide, ~-NAD,  ADPR, and cADPR were 
made in double-distilled H20.  The standard curve for nicotin- 
amide ranged from 5 to 115/zM; for/~-NAD, from 2 to 47 #M; 
for ADPR, from 3 to 54 #M; and for cADPR, from 0.24 to 5.8 
/zM. The coefficient of variation was <15%,  and controls were 
within 10% of their true value for all experiments. 
~esults 
Effects of CD38 Ligation in Cultures of Normal B Cell Pro- 
genitors andMature  B Cells.  To investigate the effects of CD38 
perturbation on the growth of normal B cell progenitors, 
we purified B lymphoid cells from normal bone marrow 
samples by use of magnetic beads conjugated to CD19 (a pan-B 
cell  marker),  seeded  them  onto  allogeneic bone  marrow 
stromal layers, and added CD38 antibodies (T16 or IB4) to 
the cultures. We used triple-color immunofluorescence and 
flow cytometry to quantify the effects of CD38 ligation at 
different stages of normal B cell differentiation. At the end 
of the cultures, cells were stained with antibodies to CD19, 
CD34, and surface Ig (slg) simultaneously, permitting rec- 
ognition of rdatively immature (CD34 +) and mature (slg +) 
subpopulations,  as well as a third group of cells  (CD19 + 
CD34-slg-)  at an intermediate level of differentiation. In 
all samples,  CD34 and slg were consistently expressed by 
different cell subpopulations. 
In five experiments, >90% of the CD19 + cells were also 
CD38 + before culture (Fig.  1 A).  Addition of anti-CD38 
markedly reduced cell recovery after 7 d of culture, compared 
with control cultures with isotype-matched nonreactive an- 
tibodies (Fig.  1, B and C). Cell loss was particularly severe 
among CD19 +  slg- B cell progenitors (mean cell recovery _+ 
SD  =  7.2  _+  11.7% of recovery in control wells). The sup- 
pressive effect of CD38 ligation extended to the most imma- 
ture CD19 +  sIg-  B lineage calls, which were identified by 
CD34 expression:  among this cell subset, mean cell recovery 
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was 7.6  +_ 2.2% of control cultures (Fig. 1 C). Anti-CD38 
antibodies also affected the recovery of bone marrow slg + 
lymphocytes, although to a lesser extent (mean cell recovery 
=  42.0  _+  23.5%; p  <0.02 by t test; Fig.  1 C). 
CD38 was expressed,  albeit weakly, on the majority of 
circulating peripheral blood B lymphocytes (Fig.  1 A).  In 
contrast to bone marrow B cells, however, recovery of these 
cells was not substantially reduced by CD38 ligation during 
culture on stromal layers. Recovery of circulating CD19 + 
slg + B cells after 7 d of culture in the presence of anti-CD38 
(T16 or IB4) was 107.0  +_  13.1% of control cultures in four 
experiments (Fig. 1, B and C). Finally, we tested the effects 
of ligating CD38 in tonsillar B lymphocytes. Virtually all 
tonsillar CD19 + B cells were CD38 +, the antigen being ex- 
pressed with the highest intensity on slgD-CD10 § cells and 
at the lowest intensity on sIgD +  CD10-  ceils, corresponding 
to germinal center and B corona cells, respectively  (33; Fig. 
1 A). Cell recovery after CD38 ligation by T16 or IB4 was 
heterogeneous but, overall, was not suppressed  as seen with 
bone  marrow  CD19 +  cells.  In  three  experiments,  cell 
recovery after 7 d of stroma coculture in the presence of anti- 
CD38  was  88.7  _+  14.6%  of control  cultures  among 
CD19 +  sIgD-  cells; within the CD19 +  sIgD + subset,  rela- 
tive cell recovery was 91.3 _+  18.2%  (Fig. 1, B and C). Thus, 
ligation of CD38 markedly suppressed cell recovery of bone 
marrow B cells but had no consistent effect on circulating 
B lymphocytes and mature reactive lymphoid cells from tonsil. 
Effects of CD38 Ligation in Cultures of Leukemic Lymphoid 
Cells and Cell Lines.  The inhibitory effects of anti-CD38 
antibodies were also seen in stroma-supported cultures of  leu- 
kemic cells. In 22 cases of ALL, all comprising donal expan- 
sions of CD19 +  sIg- B cell precursors,  CD38 was expressed 
in >90% of lymphoblasts. When anti-CD38 antibodies (T16 
or IB4) were added to the stroma-supported cultures, the cell 
recovery decreased  in all cases (mean cell recovery  =  29.1 
+  21.3%  of control cultures). 
Next, we studied CD38 function in continuously growing 
leukemic cell lines that are phenotypically equivalent to normal 
immature lymphoid cells. In the six cell lines of immature 
B cell origin (RS4;11, OP-1, 380, REH, 697, NALM6), anti- 
CD38 inhibited growth on stromal layers (range of mean cell 
recoveries after 4 d of culture ~  7.0-32.7%; Table 1). Similar 
inhibitory activity was observed with CD38 + lines of T cell 
origin (MOLT4 and CEM-C7). In contrast, the suppressive 
effects of CD38 on the EBV-transformed (EBV J.R.) and the 
Burkitt's lymphoma (RAJI) cell lines (both CD38 +) cul- 
tured on stroma were much tess marked or essentially absent 
(mean cell recovery =  85.7% and 99.0%, respectively;  Table 1). 
The inhibitory effects of anti-CD38 on immature lymphoid 
cells were dose dependent and achieved 90% of the maximal 
effect at a concentration of 0.4 #g/ml. Surprisingly, in par- 
allel stroma-free cultures, neither of the two anti-CD38 an- 
tibodies suppressed cell growth of immature lymphoid cells 
(Table 1).  We considered the possibility that stroma could 
act as a cross-linker  of CD38 antibodies. However, F(ab')2 
fragments of IB4 also had an inhibitory effect on the growth 
of immature lymphoid cell lines, although this was less po- 
tent than that observed with the whole antibody molecule. A.  Bone Marrow 
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FigtL~ 1.  CD38 expression and the effect of 
CD38 ligation in normal B cells at different 
stages of differentiation. (.4) Flow cytometric 
dot plots of CD38 expression in CD19 + cells 
from bone marrow, tonsil, and peripheral blood. 
In bone marrow B cells,  CD38  expression is 
at the highest levels: slg- and a proportion of 
slg §  cells  are  strongly  CD38+.  In  tonsil, 
CD38  levels are higher among  slgD-  cells. 
PBL  are either  weakly  CD38 +  or  CD38-. 
(B) Isometric contour plots showing flow cyto- 
metric analysis  of cells labeled with the indi- 
cated antibodies.  Highly enriched bone marrow, 
peripheral  blood,  and  tonsillar  B  cells  were 
cultured for 7  d  on allogeneic bone marrow 
stroma with a nonreactive antibody or anti- 
CD38 (T16).  Addition of anti-CD38 antibody 
markedly reduced the number of CD19 + slg- 
immature bone marrow B cells recovered, but 
did not decrease  the recovery of CD19+slg + 
peripheral  blood  B  cells,  CD19+slgD §  or 
CD19+slgD-  tonsil cells.  (C)  Cell recovery 
(mean _+ SD) ofanti-CD39 treated relative to 
control cultures in experiments with purified 
B  lineage cells from bone marrow  (n  =  5), 
tonsil (n  =  3), and peripheral blood (n  =  4). 
After 4-d cultures with IB4 (F(ab')2 on stroma, cell recovery 
relative to  control cultures  was 70 and 47%  in OP-1  and 
RS4;11, respectively. Thus, the inhibitory effects of anti-CD38 
antibodies in the presence of stroma do not depend on exten- 
sive antibody cross-linking. Moreover, cross-linking of anti- 
CD38 with a goat anti-mouse  antibody in the absence of 
stroma did not  alter cell recovery (data not  shown). 
To investigate whether adhesion to stroma was necessary 
to render cells responsive to anti-CD38, we cultured the im- 
mature B cell lines OP-1 and RS4;11 separated from stroma 
by a microporous membrane (Fig. 2). Separation  from stroma 
reduced but did not abolish the inhibitory effect of anti-CD38. 
Thus, adhesion to stromal layers is not strictly required for 
anti-CD38-mediated suppression  of growth, which can occur 
in  the presence of diffusible stromal  factors. 
In situ staining of bone marrow stromal layers revealed no 
CD38 expression on fibroblasts and low CD38 expression 
on occasional large,  round,  macrophage-like cells (data not 
shown).  However, to test the possibility that the effects of 
anti-CD38 were indirectly induced by stimulation of stroma, 
we labeled OP-1 and RS4;11 immature B cells with anti-CD38, 
removed excess antibody by washing, and seeded cells onto 
stroma. Reduction in cell recovery was virtually identical to 
that of parallel experiments in which the antibody was directly 
added to the cultures (data not shown). We also considered 
the possibility that ligation of CD38 on progenitor cells could 
induce the production of factors which, in turn, would stimu- 
late stromal cells to secrete inhibitory molecules. To test this 
possibility, we performed experiments in which one of two 
cell lines,  CEM-C7 and 380, was individually labeled with 
anti-CD38 and mixed with unlabeled cells of the other line. 
After culture on stromal layers, cell recovery was reduced only 
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Cell recovery with  anti-CD38* 
Cell line  Phenotype  (CD)*  With  stroma  Without  stroma 
% 
B  lineage ALL 
RS4;11  19 §  34-,  10-,  20-  13.3  _+  7.2  96.5  +  7.8 
OP-1  19 §  34 §  10 §  20-  32.7  _+  17.8  104.7  _+  4.2 
380  19 §  34-,  10 §  20 +  7.0  _+  7.0  116.1  +  10.9 
REH  19 §  34-,  10 §  20-  22.3  +  5.5  105.3  _+  4.9 
697  19 §  34-,  10 §  20 +  11.8  +  2.1  102.3  _+  3.8 
NALM6  19 §  34-,  10 §  20-  31.3  +  9.0  114.3  _+  12.5 
T-lineage ALL 
MOLT4  7 §  3-,  4-,  8 +  39.8  _+  1.5  96.0  _+  1.4 
CEM-C7  7 §  3-,  4 §  8-  16.7  +  0.6  97.2  +  0.5 
Burkitt's lymphoma 
RAJI  19 +,  34-,  10 §  20 §  99.0  +  11.5  110.5  _+  18.1 
B-lymphoblastoid 
EBV J.R.  19 §  34-,  10-,  20 §  85.7  _+  10.7  98.2  _+  6.0 
* CD  numbers are indicated. All lines were CD38 +.  T  lineage cell lines MOLT4 and CEM-C7 were cytoplasmic CD3 +. 
* Values represent percentage of cell recovery (mean  _+ SD of at least three experiments)  relative to control cultures  with isotype-matched nonreac- 
tive antibodies after 4 d  of culture with anti-CD38 (T16  or IB4). 
in the cells prelabeled with  CD38  (Fig. 3).  Thus,  the  sup- 
pressive effects of adding CD38 antibodies to cultures are due 
to signal transduction directly caused by CD38 ligation and 
are not  indirect effects due  to  stimulation  of stromal cells. 
Finally, we investigated whether  cells could  be rendered 
100 
8o 
2O 
sensitive to anti-CD38  by stroma-derived cytokines instead 
of stromal layers. The immature B  cell lines RS4;11,  OP-1, 
380,  REH,  697,  and NALM6  were incubated with IL-7 (25 
ng/ml),  I1,3 (10 ng/ml),  and/or SCF (20 ng/ml),  with and 
IO0 
8O 
No Contact 
CEM-C7  380 
RS4;11  OP-1 
Figure  2.  Suppression of cell growth by CD38 ligation is greater when 
immature lymphoid cells are cultured in contact with stromal layers. Cells 
were cultured either in direct contact with stromal layers or separated from 
stroma by a microporous membrane (Transwell; Costar Corp.). Bars (mean 
•  SD of quadruplicate tests) represent  percentage of cell recovery after 
4 d with anti-CD38 antibody (T16) relative to parallel cultures without 
anti-CD38. Contact with stroma enhances growth suppression by anti- 
CD38 but is not a requisite. 
Figure 3.  Suppressive effects of anti-CD38 are directly caused by anti- 
body binding to immature lymphiod cells. CEM-C7 and 380 cells were 
labeled with anti-CD38 (T16) antibody in separate tubes. Excess antibody 
was removed and labeled cells of one line were mixed in equal numbers 
with unlabeled cells of the other line. Cell mixtures were seeded onto 
stromal layers for 48 h, and cell numbers were counted by flow cytometry 
after staining with CD7 (positive on CEM-C7) and CD19  (positive on 
380). Bars represent percentage (mean  .+  SD of quadruplicate tests) of 
cell recovery relative to the number of cells in cultures without anti-CD38. 
Suppressive effects are seen only in cells labeled with anti-CD38 antibody. 
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[]  IL-3+anti-CD38  Figure 4.  Induction of sensitivity of anti- 
CD38 in immature lymphoid cells  by cytokines 
in the absence of stroma. Bars (mean  _+  SD 
of the quadruplicate tests) represent percentage 
of cell recovery after 4 d of culture relative to 
parallel cultures without cytokines. I1.,7 (25 
ng/ml) had weak stimuhtory effect on 380 cells, 
which, in turn, became sensitive  to anti-CD38 
(T16). Anti-CD38 antibodies also inhibited the 
growth of RS4;11 in the presence of II,7. IL-3 
(10 ng/ml) rendered 380 cells, but not RS4;11 
cells, sensitive to anti-CD38. 
without  anti-CD38  (T16).  Addition  of anti-CD38  to cul- 
tures with IL-7 reduced cell recovery in all six cell lines, with 
a greatest effect in the 380 cells  (Fig.  4).  Recovery of 380 
cells  also decreased by >50%  when  anti-CD38  was added 
to cultures with IL-3, by >20% when SCF was the stimu- 
lant,  and by >60% when all three cytokines were used to- 
gether. IL-3 and SCF did not render cells sensitive to the sup- 
pressive effects of CD38 in the other five cell lines.  Thus, 
the stromal factors that are essential to reveal the inhibitory 
effects of anti-CD38 on the growth of immature lymphoid 
cells can be partially replaced by stroma-derived cytokines. 
Effects of CD38  Ligation  on  Cell Proliferation and Atoo  p- 
tosis.  We assessed whether  the suppressive effects of anti- 
CD38 antibodies on lymphoid progenitor cells were due to 
inhibition of cell proliferation  and/or induction of programmed 
cell death (apoptosis). When the immature B cell line OP-1 
was cultured  on stromal layers  in  the presence of an anti- 
CD38 antibody (T16),  there was a clear suppression of cell 
growth  (Fig.  5 A).  Suppression  of cell proliferation  was 
confirmed by DNA content analysis, which showed an "~50% 
decrease in the percentage of cells in the proliferative phases 
of the cell cycle,  with  a corresponding  increase  of ceils in 
G0/G1,  after cuhure with anti-CD38;  similar observations 
were made with  the cell line RS4;11  (Table  2). 
The kinetics of anti-CD38-mediated effects were different 
in leukemic lymphoblasts from a patient with ALL. Addi- 
tion  of CD38 antibodies to  stroma-supported  cultures in- 
duced a dramatic reduction in cell number during  the first 
24 h of culture (Fig. 5 B). Cell numbers progressively declined 
during further culture.  This suggested that  CD38 ligation 
could exert a cytotoxic effect on progenitor cells in addition 
to the cytostatic effect seen with the cell lines. Thus, we quan- 
titated the percentage of cells with fragmented DNA, a char- 
acteristic of apoptosis, after anti-CD38  addition to the cul- 
tures.  In  the case of ALL illustrated  in Fig.  5 B, 44%  of 
leukemic lymphoblasts had fragmented DNA after 24 h of 
culture with anti-CD38 versus 8% in control cultures. DNA 
fragmentation  was  also  detectable  after  CD38  ligation  in 
stroma-supported cultures of cell lines.  After 24-48 h of cul- 
ture, 18% apoptotic cells with anti-CD38 versus 8% in con- 
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Figure 5.  Kinetics of suppression of immature lymphoid cells  by CD38 
ligation.  Cells from one immature B cell line (OP-  1; A) and one case 
of ALL (B) were seeded onto stromal layers and harvested daily from sepa- 
rate wells, resuspended in equal volumes, and counted by flow cytometry. 
Results  are expressed as percentage of viable CD19 + cells counted  at 
different time points relative to those originally seeded. Empty circles in- 
dicate values (mean of triplicate counts; SD <10%) obtained in control 
cultures, while solid circles are values obtained in cultures containing  anti- 
CD38 antibody (T16). In cultures of OP-1 (A), addition of anti-CD38 
suppressed cell growth throughout the culture period. In leukemic lym- 
phoblasts from a child with ALL (B), addition of CD38 antibody caused 
a rapid decline in cell numbers, which continued throughout the culture 
period. 
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CD38 Ligation* 
RS4;11  OP-1 
Phase  Control  Anti-CD38  Control  Anti-CD38 
%  % 
G0/G1  75  89  57  77 
S  22  10  40  22 
G2/M  3  1  3  1 
* DNA content analysis was performed after 48 h on stromal layers  with 
anti-CD38 (T16) or isotype-matched  control antibody. Three experiments 
were performed; results of one representative experiment are shown. 
trol cultures were seen with OP-1, while 29 versus 2% were 
detected with  CEM-C7  (Fig.  6).  These results  show that 
CD38 ligation can suppress  growth by both inhibition  of 
DNA  synthesis  and  induction  of apoptosis. 
Antibodies to CD38 Do Not Alter NAD+ Hydrolase  or ADPR 
Cyclase Activity in Immature Lymphoid Cells.  The amino acid 
sequence of CD38 is homologous to that of the enzyme ADP- 
ribosyl cyclase first isolated from the sea mollusk Aplysia califor- 
nica (13), and CD38 catalyzes the conversion of NAD +  to 
nicotinamide and cADPR,  and  that  of cADPR  to ADPR 
(9, 15-19). It has been shown that cADPR is a costimulant 
of mitogencity in routine lymphocytes (9). To investigate the 
effects of CD38 ligation on NAD +  hydrolysis and cADPR 
production,  we measured changes in extracellular levels of 
NAD +,  nicotinamide,  ADPR,  and cADPR by HPLC. As 
illustrated in Fig.  7, NAD+  levels rapidly decreased when 
added to OP-1 cells. In parallel, nicotinamide,  ADPR,  and 
cADPR levels increased. In the presence of anti-CD38 anti- 
bodies,  results  were  virtually  identical  to  cells  incubated 
without  anti-CD38.  Thus,  neither NAD+  hydrolysis nor 
cADPR or ADPR production was affected by CD38  liga- 
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Figure 7.  Assessment  of NAD + hydrolase  and ADPR cyclase  activity 
in OP-1 immature B calls in the presence or absence of anti-CD38 anti- 
body. The disappearance  of substrate (NAD +) and the appearance  of prod- 
ucts (nicotinamide, ADPR,  and cADPR) was not affected by CD38- 
ligation. 
tion. When no NAD +  was added to the cells, none of its 
metabolites  was  detectable. 
The lack of effects on the enzymatic activity were cor- 
roborated by experiments in which the effects of nicotinamide, 
NAD+,  ADPR,  and cADPR on cell growth were tested. 
We added various concentrations of nicotinamide, NAD +, 
ADPR, and cADPR to stroma-supported cultures of normal 
bone  marrow  CD19 +  cells  (one  sample),  B  lineage  ALL 
cells  (one  sample),  and  the  cell lines  NALM6,  OI)-1  and 
RS4;11. Nontoxic concentrations of nicotinamide (5-500/~M), 
NAD+  (5-50/~M), ADPR (5-50/~M), and cADPR (2.5-100 
/~g/ml) neither changed cell recovery in the absence of CD38 
antibodies nor offset the inhibitory effects of anti-CD38. The 
results of experiments with RS4;11 are shown in Fig. 8. These 
results suggest that the effects of CD38 ligation are not due 
to changes in the NAD +  hydrolase or ADPR  cyclase ac- 
tivity of CD38. 
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Figure 6.  Ligation of CD38 induces apop- 
tosis in immature lymphoid cells. Flow cyto- 
metric dot plots illustrate  DNA content versus 
DNA fragmentation studied in CEM-C7 cells 
cultured for 24 h on stroma with or without 
anti-CD38 (T16). Anti-CD38 causes the ap- 
pearance of cells with fragmented DNA and 
subnormal DNA  content,  characteristic of 
apoptosis. 
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Figure  8.  Effects  of NAD + (50 #M), nicotinamide (500/~M), ADPR 
(50/~M), and cADPR (50 #g/ml) on stroma-supported 2-d cultures of 
RS4;11 immature B cells in the presence or absence of anti-CD38 anti- 
body (T16). Bars (mean _+ SD of quadruplicate tests) represent percentage 
of cell recovery relative to control cultures with no additives. 
Discussion 
This study demonstrated  that ligation  of CD38 inhibits 
the growth of human immature lymphoid cells. Antibodies 
to  CD38  caused  a  drastic  cell  reduction  in  cultures  of 
CD19 + B cells  from normal  bone marrow,  leukemic cells 
from 22 ALL cases, and 8 immature lymphoid cell lines. The 
effects of anti-CD38 were apparent only under culture con- 
ditions approximating  those of in vivo lymphopoiesis, that 
is, in the presence of factors derived from bone marrow stromal 
cells. In the absence of these microenvironmental stimuli, the 
inhibitory  effects  of anti-CD38  were not detectable. 
The lack of inhibitory effects by anti-CD38 antibodies in 
the absence of stroma raised the possibility that the antibodies 
stimulated stromal elements to secrete factors that  suppress 
lymphopoietic cell growth. However, only rare cells among 
stromal elements exhibited CD38  expression.  In addition, 
CD38  ligation  of cell lines before seeding on  stroma was 
sufficient  to inhibit cell  growth,  and no "bystander" effect 
could be seen in untreated cells added to the same cultures. 
Finally,  growth was also partially  inhibited by anti-CD38 
when cells were exposed to cytokines in the absence of stroma. 
We conclude that the effects were due to a direct interaction 
between CD38 antibodies and lymphoid progenitors and were 
not indirectly caused by stimulation of stromal cells. The pre- 
cise relationship between CD38 ligation and microenviron- 
mental stimuli is still unknown. Sensitivity to the effects of 
anti-CD38 cannot be explained by increased intensity of CD38 
expression because this did not  substantially change when 
cells were cultured on stroma or in the presence ofcytokines 
(data not shown). Although anti-CD38 ar~tibodies also sup- 
pressed growth when cells were separated from stroma, the 
suppressive effect was greater when contact with stromal ele- 
ments was allowed, suggesting that the stromal factors that 
render cells  sensitive to anti-CD38  may be more active in 
a membrane-bound form or present at more active concen- 
trations  in  the extracellular  matrix. 
The suppressive effect of CD38 ligation on immature lym- 
phoid cells contrasts markedly with the reported stimulatory 
and anti-apoptotic effects in human and murine mature lym- 
phocytes (7-10). Another disparity of CD38 function in im- 
mature and mature lymphoid cells is its propensity to modu- 
late its expression after incubation with anti-CD38 antibodies. 
In contrast  to experiments with mature lymphocytes (12), 
we failed to detect capping or internalization  of anti-CD38 
in immature  lymphoid cells even after 20 h  of incubation 
(Kumagai M., and D. Campana, unpublished observations). 
These data taken together suggest that CD38 may have specific 
functions  at  different stages of cell maturation.  Although 
CD38  does  not  display detectable biochemical  differences 
among different cell types (34, 35), it has not been ruled out 
that different functional isoforms of CD38 exist and that they 
are expressed at different stages of maturation.  This concept 
is supported by the observation of at least five different human 
CD38 transcripts  (27) and two different transcripts for the 
murine  homolog (36). 
Our stroma-supported cultures of circulating and tonsillar 
B lymphocytes did not demonstrate  the stimulatory effects 
of anti-CD38 antibodies reported by others. However, Santos- 
Argumedo et al. (8) observed that costimulation of a CD38- 
like antibody with IL-4 was necessary to reveal clear mitoge- 
nicity in  resting  murine  B  cells.  Since no changes  in  cell 
numbers were seen when circulating B cells were challenged 
with anti-CD38 in our serum-free cultures, we conclude that 
bone  marrow  stroma  itself  does  not  act  as  a  mitogenic 
costimulus of anti-CD38.  We also failed to detect marked 
changes in numbers of tonsillar B cells labeled with anti-CD38. 
However, the short-term  antiapoptotic effects on germinal 
center cells reported by Zupo et al. (10) with one of the anti- 
bodies used in our study (IB4) could have been masked by 
an antiapoptotic effect of the stromal cells themselves in our 
7-d culture system. 
The structural homology between CD38 and ADPR cy- 
clase has  raised the hypothesis that  the function  of CD38 
on at least some cells could be related to production of cADPR, 
a compound that  functions  as a calcium-mobilizing  agent 
(9).  cADPR causes release  of intracellular  calcium in a va- 
riety of cells, including sea urchin eggs (37), pancreatic islet 
/3 cells (38), brain microsomes (39), and cardiac muscle (40). 
Although  cADPR does not  induce Ca  2+ influx or surface 
antigen modulation, it appears to induce proliferation of mu- 
rine lymphocytes stimulated with suboptimal concentrations 
of CD38,  LPS,  and Ib4  (9).  Howard et al.  (9)  speculated 
that the physiologic role of CD38 in activated lymphoid cells 
could be the extracellular  conversion of NAD +  into cADPR; 
cADPR would then be transported to an intracellular  receptor 
or directly act through a yet-unidentified cell surface receptor. 
We tested whether a similar mechanism sustained  the growth 
of lymphoid progenitor cells and whether anti-CD38 anti- 
bodies could alter CD38 enzymatic activity. However, the 
NAD+  hydrolase  and  ADPR  cyclase  activity  of CD38- 
expressing cells did not appear to be affected by CD38 liga- 
1108  Ligation  of CD38 Suppresses B Lymphopoiesis tion. The alternative speculation that CD38 is internalized 
during lymphocyte  activation and acts intracellularly does not 
seem plausible,  since CD38 in progenitor cells is not inter- 
nalized by antibody binding or by culture on stroma (data 
not shown). Above all, addition of cADPR, to the cultures, 
even at the high concentrations necessary to stimulate mu- 
rine lymphocytes (9),  did not offset the suppressive  effects 
of anti-CD38. These results suggest that, in lymphoid pro- 
genitors, CD38 could mediate signal transduction indepen- 
dently from its enzymatic activity. 
In conclusion, these data indicate that CD38 may play a 
critical role in lymphoid cell growth in the bone marrow 
microenvironment. Categories of molecules that are impor- 
tant in this setting include adhesion molecules, which par- 
ticipate in homing and stabilization of progenitor cells to bone 
marrow stromal cells, and growth factors and their receptors, 
which provide survival, proliferation, and differentiation signals 
(for reviews see references 41 and 42). CD38 interaction with 
a putative ligand would represent a new regulatory mecha- 
nism of B lymphopoiesis. We speculate that one physiologic 
role of CD38 ligation might be the conversion of a stimula- 
tory signal, for example, a cytokine signal, into an inhibitory 
one. This would provide a rapid feedback mechanism for sup- 
pressing cytokine-stimulated lymphopoiesis. 
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